Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 0.00% is 100% above its 5-year average of -187.96%, near the high end of its 5-year range (-55096.77%–5148.39%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-187.96%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
+100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 512 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$749.92M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-187.96%
Market Cap
$754.84M
Net Profit Margin
-170055.93%
TTM Avg
-70304.07%
3Y Avg
-35619.60%
5Y Avg
-24164.90%
Market Cap
$769.83M
Net Profit Margin
-34.17%
TTM Avg
-136.69%
3Y Avg
-25443.25%
5Y Avg
-23332.75%
Market Cap
$794.39M
Net Profit Margin
-4490.89%
TTM Avg
-2245.45%
3Y Avg
-2245.45%
5Y Avg
-2245.45%
Market Cap
$731.67M
Net Profit Margin
-4619.67%
TTM Avg
-3871.87%
3Y Avg
-2595.36%
5Y Avg
-1815.29%
Market Cap
$776.65M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$790.91M
Net Profit Margin
-7.58%
TTM Avg
0.29%
3Y Avg
-4.57%
5Y Avg
-4.54%
Market Cap
$734.25M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$791.64M
Net Profit Margin
-38.98%
TTM Avg
-18.01%
3Y Avg
-10.19%
5Y Avg
-2.91%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $749.92M | 0.00% | 0.00% | 0.00% | -187.96% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $754.84M | -170055.93% | -70304.07% | -35619.60% | -24164.90% |
| Geron Corporation (GERN)vs › | $769.83M | -34.17% | -136.69% | -25443.25% | -23332.75% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $794.39M | -4490.89% | -2245.45% | -2245.45% | -2245.45% |
| Anteris Technologies Global Corp. (AVR)vs › | $731.67M | -4619.67% | -3871.87% | -2595.36% | -1815.29% |
| Design Therapeutics, Inc. (DSGN)vs › | $776.65M | 0.00% | 0.00% | 0.00% | 0.00% |
| AdaptHealth Corp. (AHCO)vs › | $790.91M | -7.58% | 0.29% | -4.57% | -4.54% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $734.25M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cytek Biosciences, Inc. (CTKB)vs › | $791.64M | -38.98% | -18.01% | -10.19% | -2.91% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $710.14M | 5.93% | 9.51% | 5.53% | 9.43% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | -16396.77% |
| 2022-09-30 | -28025.81% |
| 2022-06-30 | -13383.87% |
| 2022-03-31 | -2819.35% |
| 2021-12-31 | 5148.39% |
| 2021-09-30 | -52135.48% |
| 2021-06-30 | -55096.77% |
| 2021-03-31 | -14445.16% |
| 2020-12-31 | -33800.00% |
| 2020-09-30 | -8238.71% |
| 2020-06-30 | -9277.42% |
| 2020-03-31 | -5716.13% |
